Anti-tumour activity of bisphosphonates in human myeloma cells

C M Shipman, M J Rogers, J F Apperley, R G G Russell, P I Croucher

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Multiple myeloma is a haematological malignancy characterized by an expansion of malignant plasma cells within the bone marrow and is frequently associated with bone disease involving the development of osteolytic bone lesions, pathological fractures, osteoporosis and hypercalcaemia. A class of anti-resorptive drugs known as bisphosphonates have been in use to treat osteoclast-mediated bone diseases for the past 3 decades, and are currently proving effective in the treatment of the bone disease associated with multiple myeloma. Recent studies have suggested that bisphosphonate treatment may also result in an improvement in survival in some patients with multiple myeloma. These effects on survival may reflect an indirect effect of the bisphosphonates on tumour growth, via inhibition of osteoclast activity and hence a reduction in the release of tumour growth factors. However, it is also possible that bisphosphonates may have a direct effect on myeloma cells. In support of this we have demonstrated that bisphosphonates can decrease cell proliferation and induce apoptosis in human myeloma cells in vitro, and this review discusses the possibility that bisphosphonates may have not only an anti-resorptive action, but may also have a direct anti-tumour activity.

Original languageEnglish
Pages (from-to)129-138
Number of pages10
JournalLeukemia
Volume32
Issue number1-2
DOIs
Publication statusPublished - 1998

Keywords

  • multiple myeloma
  • bisphosphonates
  • apoptosis
  • bone disease
  • multiple-myeloma
  • in-vitro
  • bone-resorption
  • induce apoptosis
  • macrophage-like
  • marrow
  • growth
  • cancer
  • malignancies
  • pharmacology

Cite this

Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G. G., & Croucher, P. I. (1998). Anti-tumour activity of bisphosphonates in human myeloma cells. Leukemia, 32(1-2), 129-138. https://doi.org/10.3109/10428199809059253